(Q84483420)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742563%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

Prognostic markers for urothelial cancer: obstacles and opportunities (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742563%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1

Per-Uno Malmström

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742563%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

publication date

1 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742563%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742563%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742563%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742563%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

516-517

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742563%20AND%20SRC:MED&resulttype=core&format=json

Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001

6 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.04.007

Survival from bladder cancer in England and Wales up to 2001.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.04.007

P53 as a prognostic marker for bladder cancer: a meta-analysis and review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.04.007

REporting recommendations for tumor MARKer prognostic studies (REMARK).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.04.007

Variability of treatment selection among surgeons for patients with cT1 urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.04.007

Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.04.007

Surgical factors influence bladder cancer outcomes: a cooperative group report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.04.007

Pathologic evaluation of radical cystectomy specimens: a cooperative group report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.04.007

The significance of central pathology review in clinical studies of transitional cell carcinoma in situ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.04.007

Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.04.007

Bladder cancer: narrowing the gap between evidence and practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.04.007

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.04.007

Predicting individual outcomes after radical cystectomy: an external validation of current nomograms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.04.007

Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.04.007

10.1016/J.UROLONC.2011.04.007

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742563%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference